Knights of Columbus Asset Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Knights of Columbus Asset Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-28,204	Closed	-$3.26M	–	396
2023 Q3	$3.26M	Buy	28,204 +11,056	+64%	+$1.19M	0.3%	104
2023 Q2	$1.76M	Sell	17,148 -152	-0.9%	-$16K	0.16%	204
2023 Q1	$1.89M	Buy	17,300 +11,505	+199%	+$1.27M	0.19%	186
2022 Q4	$659K	Sell	5,795 -63	-1%	-$5.23K	0.07%	246
2022 Q3	$363K	Sell	5,858 -242	-4%	-$16.9K	0.04%	253
2022 Q2	$487K	Buy	6,100 +52	+0.9%	+$4.92K	0.05%	250
2022 Q1	$636K	Buy	6,048 +1,900	+46%	+$185K	0.05%	238
2021 Q4	$447K	Buy	+4,148	New	+$453K	0.04%	257

Other funds holding HZNP

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

VWA

Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return

FSWA

Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Knights of Columbus Asset Advisors's HZNP Position: Q4 2023 in Review

Knights of Columbus Asset Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 28,204 shares — an estimated $3.26M sold.

Knights of Columbus Asset Advisors first reported a position in HZNP in Q4 2021 and held it in 8 quarters. The position peaked at $3.26M in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

Knights of Columbus Asset Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
Knights of Columbus Asset Advisors sold 28,204 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $3.26M.
Knights of Columbus Asset Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2021 and held it in 8 quarters.
Knights of Columbus Asset Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $3.26M in Q3 2023.
6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Knights of Columbus Asset Advisors's 13F filing for Q4 2023, filed 31 Jan 2024.